Welcome to our dedicated page for Bayer Aktien news (Ticker: BAYRY), a resource for investors and traders seeking the latest updates and insights on Bayer Aktien stock.
BAYER AG S/ADR (BAYRY) news covers developments at Bayer AG, a global life science enterprise active in health care and nutrition. Company communications highlight updates across its Pharmaceuticals Division, radiology business and crop science activities, giving investors and observers insight into how Bayer advances its pipeline and product portfolio.
Recent pharmaceutical news emphasizes growth in oncology, cardiology, neurology, immunology and women’s health. Examples include updates on asundexian for secondary stroke prevention, finerenone (Kerendia) in cardiovascular-kidney-metabolic conditions, and oncology assets such as Nubeqa for prostate cancer, Hyrnuo for HER2-mutant non-small cell lung cancer, and Xofigo for metastatic castration-resistant prostate cancer with bone metastases. Bayer also reports on Lynkuet, a hormone-free treatment for moderate to severe hot flashes due to menopause, and a Phase III SUNFLOWER study evaluating Mirena for nonatypical endometrial hyperplasia.
News items also describe Bayer’s work in radiology and molecular imaging, including the low-dose MRI contrast agent gadoquatrane and the acquisition of investigational tracers AT-01 and AT-05 for diagnosing cardiac amyloidosis. Additional coverage highlights cell and gene therapy programs for Parkinson’s disease and ophthalmic conditions, as well as collaborations such as the agreement with Soufflé Therapeutics to develop a heart-targeted siRNA therapy for a form of dilated cardiomyopathy.
On the agriculture side, Bayer Crop Science Canada announcements feature launches like Sivanto Energy for flea beetle control in canola and EverGol Rise for pulse disease control. Together, these updates illustrate how Bayer seeks to execute its mission “Health for all, Hunger for none” through pharmaceutical innovation, diagnostic imaging advances and crop protection solutions.
Bayer (OTC:BAYRY) announced global Consumer Health leadership changes on June 8, 2026 to support its Road to Billions growth strategy. The moves target faster decisions, stronger commercial execution, and expanded use of data.
New leaders include a global CMO, CDO, CCO, and a new U.S. Consumer Health President.
Bayer (OTC:BAYRY) reported full Phase III FIND-CKD results for KERENDIA (finerenone) in 1,584 adults with non-diabetic chronic kidney disease on standard of care. KERENDIA improved eGFR slope versus placebo (−3.3 vs −4.0 mL/min/1.73 m²/year; difference 0.7; p<0.001) and reduced a composite kidney-cardiovascular outcome (HR 0.77; 95% CI 0.60–0.99; p=0.043). Safety was generally similar, with serious adverse events 20.9% vs 21.2%. Hyperkalemia occurred in 17% vs 13.3%, with serious hyperkalemia <1% in both groups.
Bayer (OTC:BAYRY) will present new investigational data on KERENDIA (finerenone) at the 63rd European Renal Association Congress, June 3‑6, 2026, in Glasgow.
Highlights include first full Phase III FIND‑CKD results in non‑diabetic CKD and initial INFINITY pooled analysis across diabetic and non‑diabetic CKD populations.
Bayer (OTCMKTS:BAYRY) reported Phase II ARACOG head-to-head data showing patients on NUBEQA (darolutamide) had significantly less cognitive decline than those on enzalutamide over 24 weeks.
Median maximal cognitive decline in the primary endpoint MCCD was -15.8% with NUBEQA versus -36.1% with enzalutamide (p=0.009).
Bayer (OTC:BAYRY) will present new oncology data at the ASCO 2026 Annual Meeting in Chicago, May 29–June 2.
Sixteen abstracts cover prostate, breast, lung, salivary gland, renal cell, and colorectal cancers, including Phase II ARACOG results for NUBEQA and multiple studies of XOFIGO, HYRNUO, VITRAKVI, and STIVARGA.
Bayer (OTC:BAYRY) announced that the U.S. FDA accepted its supplemental New Drug Application and granted Priority Review for KERENDIA (finerenone) to treat adults with type 1 diabetes (T1D) and chronic kidney disease (CKD).
The sNDA is backed by Phase III FINE-ONE data showing significant six‑month UACR reduction versus placebo and pooled Phase III CKD/T2D data. Kerendia is already approved for CKD with T2D and HF with LVEF ≥40%.
Bayer (OTC:BAYRY) received U.S. FDA Priority Review for its investigational oral Factor XIa inhibitor asundexian to prevent secondary stroke after non-cardioembolic ischemic stroke or TIA.
The NDA is supported by positive Phase III OCEANIC-STROKE results, which met primary efficacy and ISTH major bleeding safety outcomes; asundexian also has FDA Fast Track status.
Bayer (OTC:BAYRY) announced that the U.S. FDA has granted Priority Review to a supplemental new drug application for HYRNUO (sevabertinib) as first-line treatment for adults with locally advanced or metastatic HER2-mutated NSCLC who have not received prior therapy, based on preliminary Phase I/II SOHO-01 data.
Bayer (OTC:BAYRY) reported Phase II ARASEC data showing NUBEQA (darolutamide) plus ADT improved outcomes in U.S. patients with metastatic castration-sensitive prostate cancer (mCSPC) versus a matched ADT-alone historical control from CHAARTED.
The regimen reduced risk of progression or death by 71% and showed significant overall survival and rPFS benefits, with no new safety signals but notable design limitations.
Bayer (OTC:BAYRY) launched the Midol in Motion campaign to help menstruators manage 7 common PMS symptoms through symptom relief and supportive movement. The program combines Midol Complete’s multi-symptom relief with guided exercise routines.
The campaign features live workout events, fitness influencer partnerships, and ongoing digital content across Midol’s social channels.